183 related articles for article (PubMed ID: 16101380)
1. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.
Uemura H; Nakaigawa N; Ishiguro H; Kubota Y
Curr Cancer Drug Targets; 2005 Aug; 5(5):307-23. PubMed ID: 16101380
[TBL] [Abstract][Full Text] [Related]
2. [Role of renin-angiotensin system in prostate cancer].
Uemura H; Kubota Y
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1228-33. PubMed ID: 19692759
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer.
Uemura H; Ishiguro H; Kubota Y
Mini Rev Med Chem; 2006 Jul; 6(7):835-44. PubMed ID: 16842133
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment.
Uemura H; Ishiguro H; Kubota Y
Int J Urol; 2008 Jan; 15(1):19-26. PubMed ID: 18184167
[TBL] [Abstract][Full Text] [Related]
5. Engagement of renin-angiotensin system in prostate cancer.
Uemura H; Hoshino K; Kubota Y
Curr Cancer Drug Targets; 2011 May; 11(4):442-50. PubMed ID: 21395553
[TBL] [Abstract][Full Text] [Related]
6. [Novel molecular targeting therapeutics for prostate cancer].
Uemura H; Nakaigawa N; Ishiguro H; Kubota Y
Nihon Rinsho; 2005 Feb; 63(2):339-44. PubMed ID: 15714989
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells.
Uemura H; Ishiguro H; Nagashima Y; Sasaki T; Nakaigawa N; Hasumi H; Kato S; Kubota Y
Mol Cancer Ther; 2005 Nov; 4(11):1699-709. PubMed ID: 16275991
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer.
Escobar E; RodrÃguez-Reyna TS; Arrieta O; Sotelo J
Curr Vasc Pharmacol; 2004 Oct; 2(4):385-99. PubMed ID: 15320819
[TBL] [Abstract][Full Text] [Related]
9. [Application of angiotensin II receptor blocker in prostate cancer].
Uemura H; Kubota Y
Nihon Rinsho; 2009 Apr; 67(4):807-11. PubMed ID: 19348246
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor.
Uemura H; Ishiguro H; Nakaigawa N; Nagashima Y; Miyoshi Y; Fujinami K; Sakaguchi A; Kubota Y
Mol Cancer Ther; 2003 Nov; 2(11):1139-47. PubMed ID: 14617787
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy.
Zhang Z; Li Z; Cao K; Fang D; Wang F; Bi G; Yang J; He Y; Wu J; Wei Y; Song X
J Hypertens; 2017 Jul; 35(7):1442-1456. PubMed ID: 28244896
[TBL] [Abstract][Full Text] [Related]
12. [Renin-angiotensin system (RAS) as new molecular therapeutic targets in prostate cancer].
Kubota Y; Uemura H
Nihon Rinsho; 2012 Sep; 70(9):1604-12. PubMed ID: 23012811
[TBL] [Abstract][Full Text] [Related]
13. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Hasegawa M; Mikami S; Oya M
Prostate; 2010 Feb; 70(2):162-9. PubMed ID: 19760626
[TBL] [Abstract][Full Text] [Related]
14. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
Bose SK; Gibson W; Giri S; Nath N; Donald CD
Prostate; 2009 Sep; 69(12):1334-42. PubMed ID: 19517575
[TBL] [Abstract][Full Text] [Related]
16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma.
Chen YH; Huang CH; Lu HI; Chen CH; Huang WT; Hsieh MJ; Rau KM; Chang AY; Lin WC; Li SH
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1185-92. PubMed ID: 24961505
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.
Uemura H; Hasumi H; Kawahara T; Sugiura S; Miyoshi Y; Nakaigawa N; Teranishi J; Noguchi K; Ishiguro H; Kubota Y
Int J Clin Oncol; 2005 Dec; 10(6):405-10. PubMed ID: 16369744
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
